Autolus Therapeutics to host Investor Conference Call to discuss AUTO1 and AUTO3 data presented at ASH and to participate in ...
November 17 2020 - 7:00AM
Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage
biopharmaceutical company developing next-generation programmed T
cell therapies, today announced that management will host an
investor conference call to discuss AUTO1 and AUTO3 data presented
at the American Society of Hematology (ASH) Virtual Congress 2020
and will also participate in the Jefferies Banking Conference:
-
19 November
2020 – Dr. Christian Itin, chairman and
chief executive officer, will participate in an analyst led
fireside chat and host virtual one-on-one meetings at the Jefferies
Virtual London Healthcare Conference at 11.25 pm ET, 4.25 pm GMT. A
live audio webcast of the fireside chat will be available on the
investor relations section of the Company’s website at Autolus. An
archived replay will be available for a period of 30 days after the
conference.
- 7
December 2020 – Dr. Christian
Itin, chairman and chief executive officer, along with the Autolus
clinical team, will host an investor call and webcast at 4.00 pm
ET, 9.00 pm GMT to discuss presentations related to its AUTO1 and
AUTO3 programs, the company’s CAR T cell therapies being
investigated in adult Acute Lymphoblastic Leukemia (ALL) and
relapsed/ refractory diffuse large B cell lymphoma (DLBCL),
respectively, during the ASH conference. To listen to the webcast
and view the accompanying slide presentation, please go to Autolus.
After the conference call, a replay will be available for a period
of one week.
About Autolus Therapeutics
plc
Autolus is a clinical-stage biopharmaceutical
company developing next-generation, programmed T cell therapies for
the treatment of cancer. Using a broad suite of proprietary and
modular T cell programming technologies, the company is engineering
precisely targeted, controlled and highly active T cell therapies
that are designed to better recognize cancer cells, break down
their defense mechanisms and eliminate these cells. Autolus has a
pipeline of product candidates in development for the treatment of
hematological malignancies and solid tumors. For more information
please visit www.autolus.com.
Contact:
Lucinda Crabtree, PhDVice President, Investor
Relations and Corporate Communications+44 (0) 7587 372
619 l.crabtree@autolus.com
Julia Wilson+44 (0) 7818
430877j.wilson@autolus.com
Susan A. NoonanS.A. Noonan
Communications+1-212-966-3650susan@sanoonan.com
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Apr 2023 to Apr 2024